Compare ATYR & DRDB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ATYR | DRDB |
|---|---|---|
| Founded | 2005 | 2024 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.2M | 320.8M |
| IPO Year | 2015 | 2024 |
| Metric | ATYR | DRDB |
|---|---|---|
| Price | $0.90 | $10.46 |
| Analyst Decision | Hold | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $4.20 | N/A |
| AVG Volume (30 Days) | ★ 2.5M | 34.2K |
| Earning Date | 03-12-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $190,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $18,728.88 | N/A |
| P/E Ratio | ★ N/A | $599.26 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.64 | $9.91 |
| 52 Week High | $7.29 | $10.55 |
| Indicator | ATYR | DRDB |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
Roman DBDR Acquisition Corp II is a blank check company.